Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 1/20 | 0.41 |
| ▸ | ACLY | P53396 | 1/20 | 0.40 |
| ▸ | FYN | P06241 | 4/20 | 0.39 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.38 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.38 |
| ▸ | KDR | P35968 | 5/20 | 0.38 |
| ▸ | CSF1R | P07333 | 1/20 | 0.38 |
| ▸ | KIT | P10721 | 1/20 | 0.38 |
| ▸ | FLT1 | P17948 | 1/20 | 0.38 |
| ▸ | FLT3 | P36888 | 1/20 | 0.38 |
| ▸ | CLK1 | P49759 | 3/20 | 0.38 |
| ▸ | FGFR1 | P11362 | 3/20 | 0.37 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.37 |
| ▸ | FGFR2 | P21802 | 2/20 | 0.37 |
| ▸ | FGFR3 | P22607 | 2/20 | 0.37 |
| ▸ | FGFR4 | P22455 | 1/20 | 0.36 |
| ▸ | AXL | P30530 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17808922 | 0.85 | KDM5B (0.41) | HSP90AA1HSP90AB1FGFR1KDM5B | |
| SCHEMBL17808920 | 0.84 | PDK2 (0.41) | HSP90AA1HSP90AB1FGFR1KDM5BFGFR2 | |
| SCHEMBL17808751 | 0.81 | RPS6KA3 (0.37) | FYNKDRFLT1KDM5B | |
| SCHEMBL17808756 | 0.80 | PTGS1 (0.36) | HSP90AA1HSP90AB1KDM5B | |
| SCHEMBL17808904 | 0.79 | TOP2A (0.36) | FYNFLT3 | |
| SCHEMBL17808902 | 0.78 | CCNE1 (0.40) | FYNKDRFLT1KDM5B | |
| SCHEMBL17808923 | 0.78 | MAPT (0.39) | — | |
| SCHEMBL19365017 | 0.76 | KDM5A (0.37) | — | |
| SCHEMBL17808905 | 0.75 | KDM5B (0.38) | KDM5B | |
| SCHEMBL19361112 | 0.75 | TP53 (0.39) | BRD4HSP90AA1HSP90AB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3227292-B1 | 4H-PYRIDO[1,2-a]PYRIMIDIN-4-ONE COMPOUNDS | ALTERITY THERAPEUTICS LTD (AU) | 2022-03-09 | — | — | EP | disclosed |
| US-20210230159-A1 | 4H-PYRIDO[1,2-A]PYRIMIDIN-4-ONE COMPOUNDS | PRANA BIOTECHNOLOGY LIMITED (AU) | 2021-07-29 | — | — | US | disclosed |
| US-11008319-B2 | 4H-pyrido[1,2-a]pyrimidin-4-one compounds | PRANA BIOTECHNOLOGY LIMITED (AU) | 2021-05-18 | — | — | US | disclosed |
| US-20200317670-A1 | 4H-PYRIDO[1,2-A]PYRIMIDIN-4-ONE COMPOUNDS | PRANA BIOTECHNOLOGY LIMITED (AU) | 2020-10-08 | — | — | US | disclosed |
| US-10738050-B2 | 4H-pyrido[1,2-A]pyrimidin-4-one compounds | PRANA BIOTECHNOLOGY LIMITED (AU) | 2020-08-11 | — | — | US | disclosed |
| US-20190352301-A1 | 4H-PYRIDO[1,2-A]PYRIMIDIN-4-ONE COMPOUNDS | PRANA BIOTECHNOLOGY LIMITED (AU) | 2019-11-21 | — | — | US | disclosed |
| US-10287285-B2 | 4H-pyrido[1,2-A]pyrimidin-4-one compounds | PRANA BIOTECHNOLOGY LIMITED (AU) | 2019-05-14 | — | — | US | disclosed |
| US-20170267676-A1 | 4H-PYRIDO[1,2-A]PYRIMIDIN-4-ONE COMPOUNDS | PRANA BIOTECHNOLOGY LIMITED (AU) | 2017-09-21 | — | — | US | disclosed |
| US-20170267676-A1 | 4H-PYRIDO[1,2-A]PYRIMIDIN-4-ONE COMPOUNDS | PRANA BIOTECHNOLOGY LIMITED (AU) | 2017-09-21 | — | — | US | disclosed |
| WO-2016086261-A1 | 4H-PYRIDO[1,2-a]PYRIMIDIN-4-ONE COMPOUNDS | PRANA BIOTECHNOLOGY LIMITED (AU) | 2016-06-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10738050-B2 | 4H-pyrido[1,2-A]pyrimidin-4-one compounds | PSEN2, PSEN1, PNPO | BRD4 962/4885ACLY 3338/4885FYN 1688/4885 |
| US-20200317670-A1 | 4H-PYRIDO[1,2-A]PYRIMIDIN-4-ONE COMPOUNDS | PSEN2, PSEN1, PNPO | BRD4 962/4885ACLY 3338/4885FYN 1688/4885 |
| US-10287285-B2 | 4H-pyrido[1,2-A]pyrimidin-4-one compounds | PSEN2, PSEN1, PNPO | BRD4 962/4885ACLY 3338/4885FYN 1688/4885 |
| US-11008319-B2 | 4H-pyrido[1,2-a]pyrimidin-4-one compounds | PSEN2, PSEN1, PNPO | BRD4 962/4885ACLY 3338/4885FYN 1688/4885 |
| US-20190352301-A1 | 4H-PYRIDO[1,2-A]PYRIMIDIN-4-ONE COMPOUNDS | PSEN2, PSEN1, PNPO | BRD4 962/4885ACLY 3338/4885FYN 1688/4885 |
| US-20210230159-A1 | 4H-PYRIDO[1,2-A]PYRIMIDIN-4-ONE COMPOUNDS | PSEN2, PSEN1, PNPO | BRD4 962/4885ACLY 3338/4885FYN 1688/4885 |
| US-20170267676-A1 | 4H-PYRIDO[1,2-A]PYRIMIDIN-4-ONE COMPOUNDS | PSEN2, PSEN1, PNPO | BRD4 962/4885ACLY 3338/4885FYN 1688/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.